

# OverExpress™ Competent Strains Purchase Order.

Fax the completed first three pages to: +33 473 644 393

*For reorders and orders not including  
C41(DE3) or C43(DE3) competent cells,,  
just fax the first two pages.*

## AVIDIS S.A.

Biopôle Clermont-Limagne  
63360 Saint Beauzire,  
France

Phone: +33 473 644 390

<http://www.overexpress.com>

By purchasing AVIDIS' OverExpress™ bacterial strain(s) (hereinafter referred to as "MATERIALS"), the recipient certifies that she or he has read, accepts and agrees to abide by the Terms and Conditions of the Research Use Only License . The recipient also certifies that the MATERIALS will be used for internal research purposes only.

AVIDIS S.A., a French Limited Company, whose address is Biopôle Clermont-Limagne, 63360 Saint Beauzire, France, (hereinafter referred to as "AVIDIS") agrees to supply to:

<b>Full Name of the Organization or Company:</b>	
<b>Name of Recipient:</b>	
<b>Position of Recipient:</b>	
<b>Delivery Address:</b>	
<b>City:</b>	
<b>State:</b>	
<b>Zip Code:</b>	
<b>Country:</b>	
<b>E-Mail Address:</b>	
<b>Phone Number:</b>	
<b>Fax Number:</b>	
<b>Billing address:</b> if different from recipient's	
<b>International V.A.T. number (for European Union only)</b>	

the following MATERIALS:

Product	Reference	Contents	Efficiency	Price (EUR)	N ordered
OverExpress™ C41(DE3) Competent Cells	CC-001A/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>300 €</b>	
OverExpress™ C43(DE3) Competent Cells	CC-002A/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>300 €</b>	
OverExpress™ C41(DE3)pLysS Competent Cells	CC-001B/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>300 €</b>	
OverExpress™ C43(DE3)pLysS Competent Cells	CC-002B/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>300 €</b>	
pAVD10 vector (for strain verification)	PL-010A/10	1 tube; 10 µl at 5ng/ml		<b>150 €</b>	
HMS174(DE3) Competent Cells*	CC-005A/10	10 tubes; 50µl each	1 x 10 <sup>7</sup> cfu/mg	<b>100 €</b>	
HMS174(DE3)pLysS Competent Cells *	CC-005B/10	10 tubes; 50µl each	1 x 10 <sup>7</sup> cfu/mg	<b>100 €</b>	
B834(DE3) Competent Cells *	CC-003A/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>100 €</b>	
B834(DE3)pLysS Competent Cells *	CC-003B/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>100 €</b>	
BL21(DE3) Competent Cells *	CC-004A/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>100 €</b>	
BL21(DE3)pLysS Competent Cells *	CC-004B/10	10 tubes; 50µl each	1 x 10 <sup>6</sup> cfu/mg	<b>100 €</b>	
OverExpress™ (DE3) Competent Cells Set	CC-011A/10	2 tubes of C41(DE3) 2 tubes of C43(DE3) 2 tubes of HMS174(DE3) 2 tubes of B834(DE3) 2 tubes of BL21(DE3) <b>10 tubes; 50µl each</b>	1 x 10 <sup>6</sup> cfu/mg	<b>180 €</b>	
OverExpress™(DE3)pLysS Competent Cells Set	CC-011B/10	2 tubes of C41(DE3)pLysS 2 tubes of C43(DE3)pLysS 2 tubes of HMS174(DE3)pLysS 2 tubes of B834(DE3)pLysS 2 tubes of BL21(DE3)pLysS <b>10 tubes; 50µl each</b>	1 x 10 <sup>6</sup> cfu/mg	<b>180€</b>	
OverExpress (DE3) Competent Cells Full Set	CC-011C/10	1 tube of C41(DE3) 1 tube of C43(DE3) 1 tube of HMS174(DE3) 1 tube of B834(DE3) 1 tube of BL21(DE3) 1 tube of C41(DE3)pLysS 1 tube of C43(DE3)pLysS 1 tube of HMS174(DE3)pLysS 1 tubes of B834(DE3)pLysS 1 tube of BL21(DE3)pLysS <b>10 tubes; 50µl each</b>	1 x 10 <sup>6</sup> cfu/mg	<b>180€</b>	
<b>TOTAL, EUR:</b>				<b>€</b>	

\* no Avidis Research Use License licence required  
All sets of competent cells are delivered with 1 x 10 µl pUC18 plasmid (concentration 0.2 ng/µl)

**Payment on reception of invoice.**  
**Shipping charges to be paid in addition.**

Address queries to:  
**Business Development Department**  
AVIDIS S.A,  
Biopôle Clermont-Limagne,  
63360 Saint Beauzire,  
France.  
Phone : + 33 473 644 272  
Fax: + 33 473 644 393  
E-mail: busdev@overexpress.com

**WE ACCEPT AND AGREE TO THE TERMS AND CONDITIONS  
OF THE RESEARCH USE ONLY LICENSE FOR OVEXPRESS™ PRODUCTS**

ORGANIZATION / COMPANY:

Department:

**Signature of Researcher:**

Print Name:

Title:

Date:

**Signature of Authorized representative of the Organization or Company:**

Print Name:

Title:

Date:

## OverExpress™ Research Use Only License

### Terms and Conditions

The OverExpress™ technology, including evolved expression strain(s) (hereinafter referred to as "MATERIALS"), is proprietary to AVIDIS S.A (hereinafter referred to as "AVIDIS").

AVIDIS provides the MATERIALS to The Licensee. The Licensee is subjected to the following Terms and Conditions:

1. AVIDIS grants, on purchase of the MATERIALS by The Licensee, a non-exclusive, non-transferable license to use said MATERIALS for The Licensee's internal research purposes only. The Licensee will use the MATERIALS in accordance with all applicable laws, regulations and governmental guidelines.

The Licensee agrees not to distribute the MATERIALS to any third parties, including recipient(s) in different department(s)/division(s) within The Licensee.

2. The MATERIALS, including their use and all parts, derivatives and progeny thereof and information related thereto, are the subject of U.S. Patent No. 6,361,966, AU Patent No. 716694, and other pending patent applications, and will remain the property of AVIDIS.

3. In accordance with scientific custom, all written or oral public disclosures concerning The Licensee's research using the MATERIALS shall include a reference as is appropriate to either U.S. Patent No. 6,361,966 and/or AU Patent No. 716694 and/or the following publication: Bruno Miroux and John E. Walker. Over-production of proteins in Escherichia coli: Mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. Journal of Molecular Biology (1996) Volume 260, pages 289–298.

4. The Licensee agrees to make no commercial use of the MATERIALS. Commercial use means use of the MATERIALS to produce a product, which product will be sold or used commercially.

For the avoidance of doubt, commercial uses include any activity for which consideration is received, for example, resale of the MATERIALS, use of the MATERIALS to provide services or in manufacturing, or use of the MATERIALS for diagnostic purposes. Such commercial uses require a Commercial Product License. Consequently, internal research purposes are all uses of the MATERIALS that are not commercial uses. Information about the Terms and Conditions of Commercial Product License can be obtained from AVIDIS Business Development Director.

Biopôle Clermont-Limagne,  
63360 Saint Beuzire,  
France.  
Fax: + 33 473 644 393 E-mail: [busdev@overexpress.com](mailto:busdev@overexpress.com)

5. AVIDIS makes no representation or warranty, express or implied, as to the identity, ownership, purity, utility, safety or activity of the MATERIALS, and nor shall AVIDIS be liable for any loss, harm, illness or other damage or injury arising from The Licensee's receipt, handling, use or disposal of the MATERIALS.

AVIDIS makes no representation or warranty that use of the MATERIALS will not infringe rights of third parties. In particular, The Licensee's attention is drawn to the fact that the C41(DE3) and C43(DE3) strains contain the T7 RNA polymerase gene. The use of the T7 expression system, developed at Brookhaven National Laboratory under contract with the U.S. Department of Energy and comprising bacteria, bacteriophages and plasmids containing the T7 RNA polymerase gene, is the subject of patent applications assigned to Brookhaven Science Associates LLC. A Licence is required in the United States of America for any commercial use, including use of the T7 system for research purposes or for production purposes by any commercial entity.

6. In case of material breach of this agreement by The Licensee, The Licensee will receive from AVIDIS a written notice to cure the breach within sixty (60) calendar days. In the absence of documented cure of the breach by The Licensee within the sixty (60) day period, AVIDIS will have the right to terminate this agreement without any compensation to The Licensee. In the event of termination hereunder, The Licensee shall destroy all MATERIALS, including all parts, derivatives and progeny thereof, and The Licensee shall provide written certification to that effect, executed by a duly authorized representative, to AVIDIS within thirty (30) days thereafter.

7. The Licensee agrees to be listed as a Research Use Only licensee of the OverExpress™ technology on AVIDIS' documentation, e.g. website, etc.

8. This agreement constitutes the entire understanding between AVIDIS and The Licensee (the PARTIES) with respect to the subject matter hereof, and supersedes and replaces all prior agreements, understanding, writings and discussions between the PARTIES relating to the said subject matter.

By signing the Purchase Order of the MATERIALS, the recipient certifies that she or he has read, accepts and agrees to abide by the above Terms and Conditions of the Research Use Only License.